Conference abstract · 23 Jun 2025
Conference abstractPublished 30 Jun 2016
Kynurenines inhibits the ability of memory CD4 T-cells to respond to IL-2 through generation of ROS during the primary HIV-1 infection
INRS-Institut Armand Frappier, Laval, Quebec, Canada
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The first months of HIV-1 infection are crucial for the establishment of the chronic phase of the infection and the disease progression. Indeed, the early infection is crucial for establishing the reservoirs and, thus, the chronic phase. The objective of this study is to analyse the underlying mechanisms responsible for reduced response of memory T-CD4 to IL-2 cytokine in early HIV infection involving deregulated metabolism. We demonstrate a clear correlation between the inflammation markers (sCD14, IL-6) of primary HIV-1-infected subjects (PHI) and the capacity of their T-CD4 to respond poorly to IL-2. This is validated by the lower level of induced phospho-STAT5 (pSTAT5) expression when compared to uninfected controls. Our results demonstrate that this impaired response to IL-2 results in the cell's inability to properly protect themselves from the Fasmediated cell death. Moreover, we demonstrate that the reduced response to IL-2 in memory CD4 T-cells from PHI directly involves the generation of reactive oxygen species (ROS). Interestingly, we also show that it is possible to partially restore the cytokine response in memory CD4 T-cells from PHI by treating the cells with n-acetyl cysteine (NAC), an antioxidant. We recently showed that kynurenines, derived from tryptophan metabolism, are clearly responsible for inhibiting IL-2 response through the oxidative stress. Finally, our study also reveals that the administration of early antiretroviral treatment leads to the restoration of IL-2 response in these subjects. Our study provides for the first time a link between the impaired memory T-CD4, the oxidative stress and kynurenine production during the first months of HIV-1 infection. This work is currently in submission in Journal of Clinical Investigation.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Antivirals & Antiretrovirals.
Conference abstract · 23 Jun 2025
Exploring signature proteins to design a novel multi-epitope vaccine candidate against Mycobacterium tuberculosis: An in-silico approach
Conference abstract · 23 Jun 2025
Correlation Between the Rh/ABO system and infection due to sars cov2 in morocco
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Antivirals & Antiretrovirals
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Julien van Grevenynghe”
